Longbow Finance’s MiNK Therapeutics INKT Stock Holding History

Longbow Finance’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$209K	Hold	16,667	–	–	0.02%	60
2026 Q2	$195K	Hold	16,667	–	–	0.02%	59
2026 Q1	$176K	Hold	16,667	–	–	0.03%	55
2025 Q4	$186K	Hold	16,667	–	–	0.03%	61
2025 Q3	$233K	Hold	16,667	–	–	0.02%	68
2025 Q2	$123K	Hold	16,667	–	–	0.01%	70
2025 Q1	$144K	Hold	16,667	–	–	0.02%	79
2024 Q4	$116K	Hold	16,667	–	–	0.01%	71
2024 Q3	$125K	Hold	16,667	–	–	0.01%	86
2024 Q2	$158K	Hold	16,667	–	–	0.02%	84
2024 Q1	$151K	Hold	16,667	–	–	0.02%	83
2023 Q4	$178K	Buy	+16,667	New	+$174K	0.02%	62
2023 Q2	–	Sell	-16,667	Closed	-$316K	–	62
2023 Q1	$316K	Hold	16,667	–	–	0.04%	59
2022 Q4	$435K	Buy	+16,667	New	+$391K	0.06%	56

Other funds holding INKT

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

DnB Asset Management Oslo, Norway $38B AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

BSC

BOLTON SECURITIES CORPORATION Bolton, Massachusetts $2.66B AUM 30.52% 1-Year Est. Return

Steward Partners Investment Advisory New York $21.5B AUM 22.23% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return

Longbow Finance's INKT Position: Q3 2026 in Review

Longbow Finance held its MiNK Therapeutics (INKT) position steady in Q3 2026 at 16,667 shares worth $209K. The position accounts for 0.02% of the portfolio, ranked #60.

Longbow Finance first reported a position in INKT in Q4 2022 and has held it in 14 quarters since. The position peaked at $435K in Q4 2022. 22 funds tracked by Wall St. Rank hold INKT as of Q3 2026.

Longbow Finance held 16,667 shares of MiNK Therapeutics worth $209K as of Q3 2026.
Longbow Finance left its MiNK Therapeutics share count unchanged in Q3 2026.
MiNK Therapeutics made up 0.02% of Longbow Finance's portfolio in Q3 2026, its #60 holding.
Longbow Finance first reported a position in MiNK Therapeutics in Q4 2022 and has held it in 14 quarters since.
Longbow Finance's MiNK Therapeutics position peaked at $435K in Q4 2022.
22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.

Based on Longbow Finance's 13F filing for Q3 2026, filed 13 Nov 2026.